Icodextrin (peritoneal ultrafiltration) vs PolyCore
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Peritoneal ultrafiltration · full Heart Failure pipeline
Icodextrin (peritoneal ultrafiltration) · Extraneal
Marketed by Vantive Health
NCT00368641 · Phase 2 · terminated
A randomized, open-label study of peritoneal ultrafiltration with icodextrin versus standard therapy in 12 participants with heart failure, terminated before any participant completed the treatment period. The posted primary, all-cause hospitalization rate, has no statistical analysis and rests on a handful of participants, so the result cannot be determined.
Reported efficacy
All-cause Hospitalization (Unadjusted) (6 to 24 months): All-cause Hospitalization (Unadjusted) (6 to 24 months): Intervention Group 5.33 hospitalizations per year (95% CI 3.13 to 9.05) vs Standard Therapy 1.69 hospitalizations per year (95% CI 0.95 to 2.99) (unclear)
Result source: NCT00368641
PolyCore
Developed by Iperboreal Pharma
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT03994874 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Heart Failure
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Icodextrin (peritoneal ultrafiltration) | PolyCore |
|---|---|---|
| CV death or HF hospitalisation | —Not reported | —Not reported |
| HF hospitalisation | —Not reported | —Not reported |
| CV death | —Not reported | —Not reported |
| KCCQ clinical summary, change | —Not reported | —Not reported |
CV death or HF hospitalisation
- Icodextrin (peritoneal ultrafiltration)
- —Not reported
- PolyCore
- —Not reported
HF hospitalisation
- Icodextrin (peritoneal ultrafiltration)
- —Not reported
- PolyCore
- —Not reported
CV death
- Icodextrin (peritoneal ultrafiltration)
- —Not reported
- PolyCore
- —Not reported
KCCQ clinical summary, change
- Icodextrin (peritoneal ultrafiltration)
- —Not reported
- PolyCore
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
PolyCore: no structured comparison results are available for Heart Failure.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Icodextrin (peritoneal ultrafiltration): 2 of 4 rows · PolyCore: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Icodextrin (peritoneal ultrafiltration) |
|---|---|
| Dropout rate | n/a: no completion milestone NCT00368641 · Phase 2 · monotherapy · Heart Failure · phase 2 |
| Discontinued due to AEs | 33.3% NCT00368641 · Phase 2 · monotherapy · Heart Failure · phase 2 |
| Serious AEs | — NCT00368641 · Phase 2 · monotherapy · Heart Failure · phase 2 |
| Most frequent reported AEs | cardiac failure congestive 50% catheter site pain 50% catheter site infection 33.3% NCT00368641 · Phase 2 · monotherapy · Heart Failure · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Icodextrin (peritoneal ultrafiltration)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Icodextrin (peritoneal ultrafiltration)'s landscape · PolyCore's landscape